This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
23 Oct 2019

The talk of the show?

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPHI WW.

Ahead of CPHI Worldwide in Frankfurt next week, Barbara Morgan, Pharmaceutical Business Director at Lubrizol Life Science Health discusses the trends she expects to be the talk of the show.

What do you think will be the major trends and talking points at CPHI Worldwide 2019?

We expect to see a continuation of the growing trend of outsourcing the full spectrum of pharmaceutical services, including commercial manufacturing. Recent figures show that only around one third of manufacturing — whether in the development stages or after commercial launch — is conducted in-house. This year, we have invested in our own commercial manufacturing capabilities with the opening of a new commercial manufacturing facility which is now up and running and recently produced its first set of three registration batches.

The ongoing growth of the biologics market over the past few years will likely be reflected on the show floor, particularly as 2019 has witnessed the FDA releasing guidelines on how biosimilars can achieve an interchangeable status and substitute the reference biologic without a prescriber intervening.

There has also been much discussion this year about the pricing pressures on generics, with regulators, patients and politicians seeking to drive down prices.

In terms of drug development trends, we expect to see an increased focus on long-acting products such as microparticle depots and implants as drug developers seek dosage forms that can aid better patient compliance. This is a topic we are keen to discuss with visitors to our stand.

What is your company hoping to achieve at this year's event?

This year we’re hoping to engage in discussions that center around GMP for clinical trial supply and commercial manufacturing. Lubrizol Life Science Health is currently well known for its focus on complex drug development projects. We’re keen to expand our client base and engage with those who are not yet familiar with our unique capabilities around commercial manufacturing of small batch size products.

What do you most look forward to about CPHI?

I enjoy how well-organized and efficient the CPHI Worldwide event is and the fact that it brings so many people in the industry together, giving you an opportunity to catch up with those clients that you don’t often see in person. It also provides a great environment for meeting new clients and prospects and learning more about the latest trends and talking points in the industry among like-minded peers.

Any presentations/events or news you'd like to tell us about?

This year our big announcement is that we will be changing our name from Particle Sciences to Lubrizol Life Science Health. The name change is an outward sign of our official transition under the Lubrizol Life Science brand umbrella.

As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation, providing customers with greater support and market insights that help them meet their goals.

Related News